From: Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer
Clinical characteristics | GM+CTCs | Total CTCs | ||||
---|---|---|---|---|---|---|
Subgroup | Range | n (Percentage) | P/Nb | P | P/N | P |
Age (years) | 48–86 |  |  | 0.770 |  | >  0.999 |
  ≤ 70 |  | 27 (50.0%) | 9/18 |  | 15/12 |  |
  > 70 |  | 27 (50.0%) | 8/19 |  | 15/12 |  |
Gleason score | 6–9 |  |  | 0.099 |  | 0.013* |
  ≤ 7 |  | 28 (51.9%) | 6/22 |  | 11/17 |  |
  ≥ 8 |  | 26 (48.1%) | 11/15 |  | 19/7 |  |
Clinical Stage | NA | Â | Â | 0.003* | Â | < 0.001* |
 I + II |  | 24 (44.4%) | 2/22 |  | 7/17 |  |
 III + IV |  | 30 (55.6%) | 15/15 |  | 23/7 |  |
Metastasis | NA | Â | Â | 0.002* | Â | 0.007* |
 No |  | 25 (46.3%) | 2/23 |  | 9/16 |  |
 Yes |  | 29 (53.7%) | 15/14 |  | 21/8 |  |
tPSA (ng/mL) | 0.01–6000.0 |  |  | 0.003* |  | 0.017* |
  ≤ 20 |  | 24 (44.4%) | 2/22 |  | 9/15 |  |
  > 20 |  | 30 (55.6%) | 15/15 |  | 21/9 |  |
fPSA/tPSA | 2.24–50.68 |  |  | 0.965 |  | 0.322 |
  ≤ 15% |  | 32 (59.3%) | 10/22 |  | 16/16 |  |
  > 15% |  | 22 (40.7%) | 7/15 |  | 14/8 |  |
ALP (U/L) | 44–718 |  |  | 0.200 |  | 0.808 |
  ≤ 90 |  | 26 (48.1%) | 6/20 |  | 14/12 |  |
  > 90 |  | 28 (51.9%) | 11/17 |  | 16/12 |  |
Hb (g/L) | 71–162 |  |  | 0.507 |  | 0.625 |
  ≤ 120 |  | 25 (46.3%) | 9/16 |  | 13/12 |  |
  > 120 |  | 29 (53.7%) | 8/21 |  | 17/12 |  |